Generate Biomedicines
Founded Year
2018Stage
Series C | AliveTotal Raised
$643MLast Raised
$273M | 1 yr agoMosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
-68 points in the past 30 days
About Generate Biomedicines
Generate Biomedicines runs a therapeutics company. It focuses on a machine learning-powered generative biology platform to create new drugs on demand across a wide range of biological modalities. The company was founded in 2018 and is based in Somerville, Massachusetts.
Loading...
ESPs containing Generate Biomedicines
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The AI antibody discovery & development platforms market uses AI/ML algorithms to streamline and optimize the process of discovering and developing antibodies for therapeutic use. This market offers a range of solutions that enable the rapid identification of potential targets and the design of optimized antibody candidates. By using AI-powered platforms, researchers can reduce the time and cost a…
Generate Biomedicines named as Highflier among 15 other companies, including AbCellera, AbSci, and Adimab.
Loading...
Research containing Generate Biomedicines
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Generate Biomedicines in 4 CB Insights research briefs, most recently on Feb 27, 2024.
Feb 27, 2024
The generative AI boom in 6 charts
Oct 25, 2023 report
State of Digital Health Q3’23 Report
Aug 29, 2023
The pharma AI market mapExpert Collections containing Generate Biomedicines
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Generate Biomedicines is included in 6 Expert Collections, including Unicorns- Billion Dollar Startups.
Unicorns- Billion Dollar Startups
1,244 items
Artificial Intelligence
14,767 items
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
Digital Health
11,072 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Drug Discovery Tech Market Map
221 items
This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.
AI 100
100 items
Generative AI
863 items
Companies working on generative AI applications and infrastructure.
Generate Biomedicines Patents
Generate Biomedicines has filed 3 patents.
The 3 most popular patent topics include:
- animal viral diseases
- betacoronaviruses
- viral respiratory tract infections
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
5/5/2023 | 5/28/2024 | Betacoronaviruses, Virus families, Animal viral diseases, Viral respiratory tract infections, Zoonoses | Grant |
Application Date | 5/5/2023 |
|---|---|
Grant Date | 5/28/2024 |
Title | |
Related Topics | Betacoronaviruses, Virus families, Animal viral diseases, Viral respiratory tract infections, Zoonoses |
Status | Grant |
Latest Generate Biomedicines News
Sep 14, 2023
14-09-2023 A company founded by Flagship Pioneering, Generate Biomedicines, has raised over a quarter of a billion dollars in a series C financing round. Launched in 2020 after two years of foundational research in Flagship’s Labs unit, the company is using a machine-learning-powered generative biology platform to develop novel therapeutics. The financing round attracted a number of new investors including Amgen (Nasdaq: AMGN), NVentures and MAPS Capital,… This article is accessible to registered users, to continue reading please register for free . A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login . If your trial has come to an end, you can subscribe here. • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. • Daily roundup of key events in pharma and biotech. • Monthly in-depth briefings on Boardroom appointments and M&A news. • Choose from a cost-effective annual package or a flexible monthly subscription. If you are already a registered user please login . The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed Chairman, Sanofi Aventis UK
Generate Biomedicines Frequently Asked Questions (FAQ)
When was Generate Biomedicines founded?
Generate Biomedicines was founded in 2018.
Where is Generate Biomedicines's headquarters?
Generate Biomedicines's headquarters is located at 101 South Street, Somerville.
What is Generate Biomedicines's latest funding round?
Generate Biomedicines's latest funding round is Series C.
How much did Generate Biomedicines raise?
Generate Biomedicines raised a total of $643M.
Who are the investors of Generate Biomedicines?
Investors of Generate Biomedicines include Fidelity Investments, Altitude Life Science Ventures, Morningside Venture Partners, ARCH Venture Partners, Flagship Pioneering and 11 more.
Who are Generate Biomedicines's competitors?
Competitors of Generate Biomedicines include JURA Bio and 3 more.
Loading...
Compare Generate Biomedicines to Competitors
Therapeutics Data Commons focuses on artificial intelligence for therapeutic science within the biomedical and pharmaceutical sectors. The company offers AI-solvable tasks, AI-ready datasets, and curated benchmarks to support the development and evaluation of AI methods in drug discovery and development. Therapeutics Data Commons primarily serves biochemical, biomedical, and machine learning scientists with resources for algorithmic and scientific advances in therapeutic applications. It was founded in 2021 and is based in Cambridge, Massachusetts.
LabGenius serves as a biopharmaceutical company focused on the discovery of medicines through the integration of machine learning, synthetic biology, and robotic automation. The company's main offerings include the development of next-generation therapeutic antibodies using a smart robotic platform, EVA, which designs and learns from its own experiments to improve the drug discovery process. LabGenius primarily serves sectors involved in the treatment of cancer and inflammatory diseases. It was founded in 2012 and is based in London, United Kingdom.
BigHat Biosciences focuses on the development of advanced antibody therapeutics within the biotechnology sector. The company offers a platform that combines machine learning and synthetic biology to accelerate the antibody engineering process, aiming to produce safer and more effective treatments. BigHat Biosciences primarily serves sectors that require therapeutic antibodies, such as the healthcare and pharmaceutical industries. It was founded in 2019 and is based in San Mateo, California.
Adimab provides biological discovery and engineering, focusing on antibodies and multispecifics. The company offers a proprietary yeast-based platform for the discovery and optimization of fully human monoclonal and bispecific antibodies, as well as the engineering of protein-based therapeutics. Adimab's services cater to pharmaceutical companies, biotechnology firms at various stages, and academic institutions seeking to develop quality therapeutic programs. It was founded in 2007 and is based in Lebanon, New Hampshire.
Insitro focuses on drug discovery and development. The company's main services involve the use of machine learning and high-throughput biology to predict successful paths for medicine creation. It aims to avoid costly failures in pharmaceutical research and development (R&D). Insitro primarily sells to the healthcare industry. It was founded in 2018 and is based in South San Francisco, California.
Molcure is a biotechnology company focused on accelerating drug discovery through the integration of AI-driven science and molecular engineering. The company offers a platform that combines machine learning, laboratory automation, and a proprietary database to generate diverse and high-quality antibodies and peptides. Molcure primarily serves the biopharmaceutical research sector, partnering with companies to discover therapeutics. It was founded in 2013 and is based in Kawasaki, Japan.
Loading...